Literature DB >> 25451027

Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL.

Sanjib Dutta1, Jeremy Ryan2, T Scott Chen1, Christos Kougentakis1, Anthony Letai2, Amy E Keating3.   

Abstract

The Bcl-2 family of proteins plays a critical role regulating apoptosis, and pro-survival Bcl-2 family members are important therapeutic targets due to their overexpression in different cancers. Pro-apoptotic Bcl-2 homology 3 (BH3)-only proteins antagonize pro-survival Bcl-2 protein functions by binding directly to them, and a sub-class of BH3-only proteins termed sensitizers can initiate apoptosis via this mechanism in response to diverse signals. The five pro-survival proteins Bcl-xL, Mcl-1, Bcl-2, Bcl-w and Bfl-1 differ in their binding preferences, with Bcl-xL, Bcl-2 and Bcl-w sharing similar interaction profiles for many natural sensitizers and small molecules. Peptides that bind selectively to just one or a subset of family members have shown utility in assays that diagnose apoptotic blockades in cancer cells and as reagents for dissecting apoptotic mechanism. Combining computational design, combinatorial library screening and rational mutagenesis, we designed a series of BH3 sensitizer peptides that bind Bcl-xL with sub-nanomolar affinity and selectivity up to 1000-fold over each of the four competing pro-survival proteins. We demonstrate the efficacy of our designed BH3 peptides in assays that differentiate between cancer cells that are dependent on different pro-survival proteins.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BH3 peptides; BH3 profiling; Bcl-2 proteins; peptide design; yeast-surface display

Mesh:

Substances:

Year:  2014        PMID: 25451027      PMCID: PMC4357494          DOI: 10.1016/j.jmb.2014.09.030

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  44 in total

1.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

Authors:  Lin Chen; Simon N Willis; Andrew Wei; Brian J Smith; Jamie I Fletcher; Mark G Hinds; Peter M Colman; Catherine L Day; Jerry M Adams; David C S Huang
Journal:  Mol Cell       Date:  2005-02-04       Impact factor: 17.970

2.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.

Authors:  Michael Certo; Victoria Del Gaizo Moore; Mari Nishino; Guo Wei; Stanley Korsmeyer; Scott A Armstrong; Anthony Letai
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

3.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

Authors:  Victoria Del Gaizo Moore; Jennifer R Brown; Michael Certo; Tara M Love; Carl D Novina; Anthony Letai
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

4.  General method for plasmid construction using homologous recombination.

Authors:  C K Raymond; T A Pownder; S L Sexson
Journal:  Biotechniques       Date:  1999-01       Impact factor: 1.993

Review 5.  The Bcl-2 protein family: arbiters of cell survival.

Authors:  J M Adams; S Cory
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

6.  Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis.

Authors:  M Sattler; H Liang; D Nettesheim; R P Meadows; J E Harlan; M Eberstadt; H S Yoon; S B Shuker; B S Chang; A J Minn; C B Thompson; S W Fesik
Journal:  Science       Date:  1997-02-14       Impact factor: 47.728

7.  Yeast surface display for screening combinatorial polypeptide libraries.

Authors:  E T Boder; K D Wittrup
Journal:  Nat Biotechnol       Date:  1997-06       Impact factor: 54.908

8.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Authors:  Tilman Oltersdorf; Steven W Elmore; Alexander R Shoemaker; Robert C Armstrong; David J Augeri; Barbara A Belli; Milan Bruncko; Thomas L Deckwerth; Jurgen Dinges; Philip J Hajduk; Mary K Joseph; Shinichi Kitada; Stanley J Korsmeyer; Aaron R Kunzer; Anthony Letai; Chi Li; Michael J Mitten; David G Nettesheim; ShiChung Ng; Paul M Nimmer; Jacqueline M O'Connor; Anatol Oleksijew; Andrew M Petros; John C Reed; Wang Shen; Stephen K Tahir; Craig B Thompson; Kevin J Tomaselli; Baole Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg
Journal:  Nature       Date:  2005-05-15       Impact factor: 49.962

9.  Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands.

Authors:  Catherine L Day; Lin Chen; Sarah J Richardson; Penny J Harrison; David C S Huang; Mark G Hinds
Journal:  J Biol Chem       Date:  2004-11-18       Impact factor: 5.157

Review 10.  Promoting apoptosis as a strategy for cancer drug discovery.

Authors:  Stephen W Fesik
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

View more
  18 in total

1.  Locating Herpesvirus Bcl-2 Homologs in the Specificity Landscape of Anti-Apoptotic Bcl-2 Proteins.

Authors:  Glenna Wink Foight; Amy E Keating
Journal:  J Mol Biol       Date:  2015-05-23       Impact factor: 5.469

2.  Peptide design by optimization on a data-parameterized protein interaction landscape.

Authors:  Justin M Jenson; Vincent Xue; Lindsey Stretz; Tirtha Mandal; Lothar Luther Reich; Amy E Keating
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-15       Impact factor: 11.205

3.  Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cells.

Authors:  Raheleh Rezaei Araghi; Gregory H Bird; Jeremy A Ryan; Justin M Jenson; Marina Godes; Jonathan R Pritz; Robert A Grant; Anthony Letai; Loren D Walensky; Amy E Keating
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-16       Impact factor: 11.205

Review 4.  Molecular evolution of peptides by yeast surface display technology.

Authors:  Sara Linciano; Stefano Pluda; Arianna Bacchin; Alessandro Angelini
Journal:  Medchemcomm       Date:  2019-07-10       Impact factor: 3.597

5.  The soy-derived peptide Vglycin inhibits the growth of colon cancer cells in vitro and in vivo.

Authors:  Chang Gao; Rui Sun; Ya-Rong Xie; An-Li Jiang; Mei Lin; Min Li; Zheng-Wang Chen; Ping Zhang; Honglin Jin; Jue-Ping Feng
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-01

6.  Quantitative mapping of binding specificity landscapes for homologous targets by using a high-throughput method.

Authors:  Lidan Aharon; Shay-Lee Aharoni; Evette S Radisky; Niv Papo
Journal:  Biochem J       Date:  2020-05-15       Impact factor: 3.857

7.  Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.

Authors:  Elisa Ten Hacken; Rebecca Valentin; Fara Faye D Regis; Jing Sun; Shanye Yin; Lillian Werner; Jing Deng; Michaela Gruber; Jessica Wong; Mei Zheng; Amy L Gill; Michael Seiler; Peter Smith; Michael Thomas; Silvia Buonamici; Emanuela M Ghia; Ekaterina Kim; Laura Z Rassenti; Jan A Burger; Thomas J Kipps; Matthew L Meyerson; Pavan Bachireddy; Lili Wang; Robin Reed; Donna Neuberg; Ruben D Carrasco; Angela N Brooks; Anthony Letai; Matthew S Davids; Catherine J Wu
Journal:  JCI Insight       Date:  2018-10-04

Review 8.  Physiological and Pharmacological Control of BAK, BAX, and Beyond.

Authors:  Mark P A Luna-Vargas; Jerry Edward Chipuk
Journal:  Trends Cell Biol       Date:  2016-08-04       Impact factor: 20.808

Review 9.  Designing helical peptide inhibitors of protein-protein interactions.

Authors:  Raheleh Rezaei Araghi; Amy E Keating
Journal:  Curr Opin Struct Biol       Date:  2016-04-25       Impact factor: 6.809

Review 10.  New dimension in therapeutic targeting of BCL-2 family proteins.

Authors:  Samaher Besbes; Massoud Mirshahi; Marc Pocard; Christian Billard
Journal:  Oncotarget       Date:  2015-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.